Session » (1055–1087) Healthcare Disparities in Rheumatology Posters

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1084

Access to rheumatology care in patients with new diagnosis of polymyalgia rheumatica: analysis from a national inception cohort

10:30AM-12:30PM: Abstract Number: 1065

Age of Disease Onset and Risk of Serious Infection with anti-TNF Use in Older Adults with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 1080

Are Minority Populations Truly Vaccine Hesitant? A Provider-Based Approach to RSV Vaccine Uptake Suggests Otherwise.

10:30AM-12:30PM: Abstract Number: 1066

Assessing Disparities in Outcomes and Processes of Care for Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network

10:30AM-12:30PM: Abstract Number: 1059

Assessing the Relationship Between Multidimensional Area Level Indicators and Lupus Disease Activity in Children

10:30AM-12:30PM: Abstract Number: 1068

Association Between Social Determinants of Health Domains and COVID-19-Related Hospitalization in Individuals with Autoimmune Rheumatic Diseases: A Retrospective Analysis of National U.S. Data

10:30AM-12:30PM: Abstract Number: 1085

Bridging the Gap: The Use of Patient Joint Self-Assessment in RA Treatment Response Evaluation

10:30AM-12:30PM: Abstract Number: 1070

Cervical Cancer and HPV Screening in Women with Lupus vs Healthy Control Group: A Retrospective Study at a Tertiary Referral Center

10:30AM-12:30PM: Abstract Number: 1064

Characterization of Juvenile Idiopathic Arthritis in Indigenous North American Children enrolled in a North American registry

10:30AM-12:30PM: Abstract Number: 1060

Demographic Risk Factors, Social Vulnerability Index, and Mortality in Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1071

Depression and Mental Health Service Gaps in Autoimmune Disease: Insights from a Simulated BRFSS Dataset

10:30AM-12:30PM: Abstract Number: 1073

Development of a Culturally-Tailored Storytelling Intervention to Improve COVID-19 Vaccine Uptake in Black and Latinx Patients with Autoimmune and Inflammatory Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 1063

Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020

10:30AM-12:30PM: Abstract Number: 1077

Health literacy and work status in people with inflammatory arthritis: a cluster analysis in a national cohort

10:30AM-12:30PM: Abstract Number: 1056

High diagnostic rate of genetic testing in adult patients with autoinflammation: A Single Center Experience

10:30AM-12:30PM: Abstract Number: 1083

How Do Social Determinants of Health Differ Across Age and Disability Groups Among Adult Medicare Advantage Enrollees with Systemic Lupus Erythematosus?

10:30AM-12:30PM: Abstract Number: 1087

Impact of Neighborhood-Level Social Vulnerability on Disease Severity, Clinical Manifestations, and Early Mortality in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 1072

Inclusion of Older Adults in Pharmacologic Randomized Controlled Clinical Trials of Autoimmune Rheumatic Diseases: A Systematic Review

10:30AM-12:30PM: Abstract Number: 1081

Insurance, Gender, and COVID-19’s Effects on Health Inequity in Rheumatoid Arthritis: A 12-Year Long Population Assessment

10:30AM-12:30PM: Abstract Number: 1067

Investigating Barriers to Care through Childhood Opportunity, Social Vulnerability, Area Deprivation, and Distance to Care in Pediatric Localized Scleroderma

10:30AM-12:30PM: Abstract Number: 1086

Leveraging Natural Language Processing to Uncover Real-World Trends in Cannabis Use from Clinic Notes in Electronic Health Records

10:30AM-12:30PM: Abstract Number: 1057

Leveraging Social Risk Factor Screening Infrastructure in Rheumatology Clinics to Respond to Rising Rates of Tuberculosis Among Individuals Experiencing Homelessness

10:30AM-12:30PM: Abstract Number: 1082

Lupus Patient Navigator Program for Improving Care Adherence for Minority Patients

10:30AM-12:30PM: Abstract Number: 1058

Prevalence of Depression Associated with Rheumatologic Medications with Labeled Warnings: Real World Evidence from a Tertiary Care Center

10:30AM-12:30PM: Abstract Number: 1075

Racial Differences in Management and Clinical Outcomes of Giant-Cell Arteritis: A Real-World Propensity-Matched Study

10:30AM-12:30PM: Abstract Number: 1076

Racial Differences in Real-World Use of Urate-Lowering and Adjunctive Therapies for Gout: A 10-Year Propensity-Matched Cohort Study

10:30AM-12:30PM: Abstract Number: 1074

Racial Disparities in Cardiovascular, Ocular, and Treatment Outcomes in US Patients with Behçet’s Disease: A Propensity-Matched Real-World Analysis

10:30AM-12:30PM: Abstract Number: 1061

Screening for Hepatitis B in a Veterans Health Administration Subpopulation with Rheumatological Disease Prior to Initiating Immunosuppressive Therapy: a retrospective study on testing and treatment within the Black American population from the VAMC in Memphis, TN

10:30AM-12:30PM: Abstract Number: 1062

Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort

10:30AM-12:30PM: Abstract Number: 1079

Sociodemographic, Clinical, and Community-Level Deprivation Factors are Associated with Health-Related Quality of Life in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1069

Strengthening Rheumatology Workforce Capacity and Impact on Patient Care in Louisiana: Expanding Fellowship Training Opportunities Through Strategic Partnerships

10:30AM-12:30PM: Abstract Number: 1055

The Price of Relief: Examining the Role of Insurance in High-Cost Medication Use

10:30AM-12:30PM: Abstract Number: 1078

Trends in Hospitalization rate with Lupus in the State of Florida: A retrospective data review from Florida Health Charts from 1992-2023

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].